229 related articles for article (PubMed ID: 29434033)
21. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
22. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
23. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
Short NJ; Kantarjian H; Jabbour E; Ravandi F
Best Pract Res Clin Haematol; 2017 Sep; 30(3):193-200. PubMed ID: 29050692
[TBL] [Abstract][Full Text] [Related]
24. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
26. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
27. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
28. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Narayanan V; Pollyea DA; Gutman JA; Jimeno A
Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
[TBL] [Abstract][Full Text] [Related]
29. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Jones D; Thomas D; Yin CC; O'Brien S; Cortes JE; Jabbour E; Breeden M; Giles FJ; Zhao W; Kantarjian HM
Cancer; 2008 Sep; 113(5):985-94. PubMed ID: 18615627
[TBL] [Abstract][Full Text] [Related]
30. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.
Kobayashi K; Mitsui K; Ichikawa H; Nakabayashi K; Matsuoka M; Kojima Y; Takahashi H; Iijima K; Ootsubo K; Oboki K; Okita H; Yasuda K; Sakamoto H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Ohara A
Br J Haematol; 2014 Jun; 165(6):836-41. PubMed ID: 24628626
[TBL] [Abstract][Full Text] [Related]
31. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract][Full Text] [Related]
32. [Research Progress on Pathogenic Genes of Ph-like Acute Lymphoblastic Leukemia--Review].
Li ZZ; Wang YJ; Feng JK; Tan JB; Zhao RB; Yang TH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):695-699. PubMed ID: 32319419
[TBL] [Abstract][Full Text] [Related]
33. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.
Kobayashi K; Miyagawa N; Mitsui K; Matsuoka M; Kojima Y; Takahashi H; Ootsubo K; Nagai J; Ueno H; Ishibashi T; Sultana S; Okada Y; Akimoto S; Okita H; Matsumoto K; Goto H; Kiyokawa N; Ohara A
Pediatr Blood Cancer; 2015 Jun; 62(6):1058-60. PubMed ID: 25400122
[TBL] [Abstract][Full Text] [Related]
34. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.
Fei F; Stoddart S; Groffen J; Heisterkamp N
Mol Cancer Ther; 2010 May; 9(5):1318-27. PubMed ID: 20388735
[TBL] [Abstract][Full Text] [Related]
35. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Hofmann WK; Komor M; Wassmann B; Jones LC; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG
Blood; 2003 Jul; 102(2):659-61. PubMed ID: 12663457
[TBL] [Abstract][Full Text] [Related]
36. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
37. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
38. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
Ishibashi T; Yaguchi A; Terada K; Ueno-Yokohata H; Tomita O; Iijima K; Kobayashi K; Okita H; Fujimura J; Ohki K; Shimizu T; Kiyokawa N
Exp Hematol; 2016 Mar; 44(3):177-88.e5. PubMed ID: 26703895
[TBL] [Abstract][Full Text] [Related]
39. The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.
Thomas X; Heiblig M
Expert Opin Drug Discov; 2016 Nov; 11(11):1061-1070. PubMed ID: 27548716
[TBL] [Abstract][Full Text] [Related]
40. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
